Free Trial
→ Watch This Robotics Demo Before July 23rd (From Brownstone Research) (Ad) Buy AKRO Stock  Free AKRO Stock Alerts

Akero Therapeutics (AKRO) Financials

Akero Therapeutics logo
$43.01 +0.99 (+2.36%)
As of 12:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Akero Therapeutics

Annual Income Statements for Akero Therapeutics

This table shows Akero Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -44 -79 -101 -112 -152 -251
Consolidated Net Income / (Loss)		 -44 -79 -101 -112 -152 -252
Net Income / (Loss) Continuing Operations		 -44 -79 -101 -112 -152 -252
Total Pre-Tax Income 		-44 -79 -101 -112 -152 -252
Total Operating Income		 -46 -80 -101 -115 -173 -285
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 46 80 101 115 173 285
Selling, General & Admin Expense		 8.61 15 19 30 31 38
Research & Development Expense		 37 65 82 85 142 247
Total Other Income / (Expense), net		 1.90 0.95 0.11 3.12 21 33
Interest Expense		 - - 0.00 0.74 3.10 4.67
Interest & Investment Income		 - - 0.11 3.86 24 38
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.01 -0.00 0.02 -0.06 -0.23 -0.68
Basic Earnings per Share		 ($2.90) ($2.52) ($2.89) ($2.87) ($2.89) ($3.75)
Weighted Average Basic Shares Outstanding		 15.07M 31.46M 34.83M 38.98M 52.57M 67.14M
Diluted Earnings per Share		 ($2.90) ($2.52) ($2.89) ($2.87) ($2.89) ($3.75)
Weighted Average Diluted Shares Outstanding		 15.07M 31.46M 34.83M 38.98M 52.57M 67.14M
Weighted Average Basic & Diluted Shares Outstanding		 15.07M 31.46M 34.83M 46.97M 56.30M 79.62M
Cash Dividends to Common per Share		 $0.00 $0.00 $0.00 - $0.00 $0.00

Quarterly Income Statements for Akero Therapeutics

This table shows Akero Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -36 -23 -26 -31 -40 -54 -54 -56 -70 -71
Consolidated Net Income / (Loss)		 -36 -23 -26 -31 -40 -55 -53 -56 -73 -70
Net Income / (Loss) Continuing Operations		 -36 -23 -26 -31 -40 -55 -53 -56 -73 -70
Total Pre-Tax Income 		-36 -22 -26 -31 -40 -55 -53 -56 -73 -70
Total Operating Income		 -36 -25 -29 -36 -47 -62 -60 -66 -82 -78
Total Operating Expenses		 36 25 29 36 47 62 60 66 82 78
Selling, General & Admin Expense		 11 7.10 6.97 7.64 7.98 8.48 9.30 10 9.47 8.73
Research & Development Expense		 25 18 22 28 39 53 51 55 72 69
Total Other Income / (Expense), net		 -0.32 3.50 2.92 4.55 6.96 6.69 6.61 9.75 9.00 8.00
Interest Expense		 0.32 0.36 0.46 0.86 0.89 0.90 0.99 1.23 1.25 1.20
Interest & Investment Income		 - - 3.38 5.40 7.84 7.58 7.60 11 10 9.20
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -0.00 -0.04 0.02 0.27 0.26 -0.78 0.35 0.18 -2.36 1.16
Basic Earnings per Share		 ($0.92) ($0.44) ($0.55) ($0.60) ($0.71) ($1.03) ($0.90) ($0.81) ($1.05) ($0.99)
Weighted Average Basic Shares Outstanding		 38.66M 38.98M 46.94M 51.87M 55.61M 52.57M 59.31M 69.16M 69.44M 67.14M
Diluted Earnings per Share		 ($0.92) ($0.44) ($0.55) ($0.60) ($0.71) ($1.03) ($0.90) ($0.81) ($1.05) ($0.99)
Weighted Average Diluted Shares Outstanding		 38.66M 38.98M 46.94M 51.87M 55.61M 52.57M 59.31M 69.16M 69.44M 67.14M
Weighted Average Basic & Diluted Shares Outstanding		 46.76M 46.97M 50.09M 55.60M 55.71M 56.30M 69.15M 69.43M 69.80M 79.62M

Annual Cash Flow Statements for Akero Therapeutics

This table details how cash moves in and out of Akero Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -11 123 -37 99 -16 106
Net Cash From Operating Activities		 -36 -71 -80 -93 -145 -230
Net Cash From Continuing Operating Activities		 -36 -71 -80 -93 -145 -230
Net Income / (Loss) Continuing Operations		 -44 -79 -101 -112 -152 -252
Consolidated Net Income / (Loss)		 -44 -79 -101 -112 -152 -252
Depreciation Expense		 0.00 0.02 0.04 0.04 0.03 0.02
Amortization Expense		 -0.10 0.08 1.07 0.19 -9.11 -13
Non-Cash Adjustments To Reconcile Net Income		 1.77 6.08 10 24 22 31
Changes in Operating Assets and Liabilities, net		 6.46 2.22 9.73 -4.46 -6.33 3.00
Net Cash From Investing Activities		 -72 -9.76 42 -64 -224 -110
Net Cash From Continuing Investing Activities		 -72 -9.76 42 -64 -224 -110
Acquisitions		 - - - 0.00 0.00 -1.00
Purchase of Investments		 -72 -115 -44 -101 -433 -516
Sale and/or Maturity of Investments		 0.00 105 86 38 210 407
Net Cash From Financing Activities		 96 203 0.60 256 353 446
Net Cash From Continuing Financing Activities		 96 203 0.60 256 353 446
Repayment of Debt		 - - 0.00 0.00 0.00 0.00
Repurchase of Preferred Equity		 - - 0.00 0.00 0.00 0.00
Repurchase of Common Equity		 0.00 0.00 -0.52 -0.86 -0.78 -0.84
Issuance of Debt		 - - 0.00 10 15 10
Issuance of Common Equity		 96 203 0.37 241 336 424
Other Financing Activities, net		 0.45 0.36 0.75 5.02 3.27 13
Cash Interest Paid		 - - 0.00 0.44 2.48 3.98

Quarterly Cash Flow Statements for Akero Therapeutics

This table details how cash moves in and out of Akero Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 196 -124 8.11 186 -175 -35 390 -313 5.71 24
Net Cash From Operating Activities		 -25 -26 -25 -22 -50 -49 -35 -57 -70 -67
Net Cash From Continuing Operating Activities		 -25 -25 -25 -22 -49 -49 -35 -57 -70 -67
Net Income / (Loss) Continuing Operations		 -36 -23 -26 -31 -40 -55 -53 -56 -73 -70
Consolidated Net Income / (Loss)		 -36 -23 -26 -31 -40 -55 -53 -56 -73 -70
Depreciation Expense		 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.02
Amortization Expense		 0.10 -0.10 -1.17 -1.26 -3.15 -3.53 -2.81 -3.29 -3.57 -2.84
Non-Cash Adjustments To Reconcile Net Income		 12 4.39 5.06 5.07 6.06 5.61 7.94 8.71 7.47 7.34
Changes in Operating Assets and Liabilities, net		 -1.02 -6.72 -2.71 5.16 -13 3.93 13 -6.88 -1.61 -1.58
Net Cash From Investing Activities		 3.00 -101 18 -128 -126 13 58 -256 73 15
Net Cash From Continuing Investing Activities		 3.00 -101 18 -128 -126 13 58 -256 73 15
Purchase of Investments		 - -101 -25 -189 -161 -58 -39 -339 -58 -80
Sale and/or Maturity of Investments		 3.00 0.00 43 61 36 71 97 85 131 95
Net Cash From Financing Activities		 218 2.72 15 337 0.81 0.50 367 -0.15 3.07 76
Net Cash From Continuing Financing Activities		 218 2.72 15 337 0.81 0.50 367 -0.15 3.07 76
Repurchase of Common Equity		 -0.38 -0.17 -0.30 -0.44 - -0.03 -0.27 -0.48 -0.06 -0.03
Issuance of Common Equity		 216 0.10 0.00 336 - 0.08 355 0.32 - 68
Other Financing Activities, net		 2.08 2.79 0.46 1.56 0.81 0.45 1.77 0.00 3.13 8.24
Cash Interest Paid		 0.19 0.25 0.28 0.67 0.77 0.77 0.77 1.09 1.09 1.03

Annual Balance Sheets for Akero Therapeutics

This table presents Akero Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 77 77 138 273 196 357 580 826
Total Current Assets		 77 77 138 271 194 355 560 770
Cash & Equivalents		 76 76 65 187 150 250 234 340
Short-Term Investments		 - - 72 81 38 102 316 403
Prepaid Expenses		 1.16 1.16 1.65 2.96 5.32 3.72 9.95 27
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.13 0.09 0.05 0.02 0.00
Total Noncurrent Assets		 0.02 0.02 0.07 1.86 1.88 1.35 20 56
Long-Term Investments		 - - - - - 0.00 19 55
Other Noncurrent Operating Assets		 0.02 0.02 0.07 1.86 1.88 1.35 1.01 0.76
Total Liabilities & Shareholders' Equity		 77 77 138 273 196 357 580 826
Total Liabilities		 2.34 2.34 9.39 15 26 30 45 76
Total Current Liabilities		 2.34 2.34 9.37 13 25 19 19 40
Accounts Payable		 1.37 1.37 0.95 3.43 6.71 7.97 7.04 9.03
Accrued Expenses		 0.97 0.97 8.42 9.68 18 11 12 31
Total Noncurrent Liabilities		 0.00 0.00 0.02 1.52 1.31 11 26 36
Long-Term Debt		 - - - - 0.00 9.54 25 35
Other Noncurrent Operating Liabilities		 0.00 0.00 0.02 1.52 1.31 1.38 0.87 0.72
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -50 -50 129 259 169 327 535 750
Total Preferred & Common Equity		 -50 -50 129 259 169 327 535 750
Total Common Equity		 -50 -50 129 259 169 327 535 750
Common Stock		 37 37 259 468 479 749 1,109 1,575
Retained Earnings		 -87 -87 -130 -210 -310 -422 -574 -826
Accumulated Other Comprehensive Income / (Loss)		 - - -0.01 -0.00 -0.03 0.04 0.27 0.95

Quarterly Balance Sheets for Akero Therapeutics

This table presents Akero Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 379 349 664 635 912 865 818
Total Current Assets		 378 347 643 576 911 776 747
Cash & Equivalents		 374 258 444 270 624 310 316
Short-Term Investments		 0.00 85 195 285 280 450 401
Prepaid Expenses		 3.94 4.27 3.76 21 7.62 16 30
Plant, Property, & Equipment, net		 0.06 0.04 0.03 0.02 0.02 0.02 0.02
Total Noncurrent Assets		 1.41 1.29 21 59 0.95 89 71
Long-Term Investments		 - - 19 58 0.00 88 70
Other Noncurrent Operating Assets		 1.41 1.29 1.13 1.07 0.95 0.88 0.82
Total Liabilities & Shareholders' Equity		 379 349 664 635 912 865 818
Total Liabilities		 36 42 47 52 66 67 79
Total Current Liabilities		 25 17 22 28 30 31 43
Accounts Payable		 6.01 7.08 10 11 14 15 25
Accrued Expenses		 19 9.60 11 15 16 17 18
Total Noncurrent Liabilities		 11 26 26 24 36 36 36
Long-Term Debt		 9.45 25 25 23 35 35 35
Other Noncurrent Operating Liabilities		 1.21 1.18 1.04 0.98 0.93 0.84 0.81
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 344 306 616 583 846 798 738
Total Preferred & Common Equity		 344 306 616 583 846 798 738
Total Common Equity		 344 306 616 583 846 798 738
Common Stock		 743 754 1,096 1,103 1,474 1,482 1,492
Retained Earnings		 -399 -448 -479 -519 -627 -683 -756
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.02 -0.25 -0.51 -0.08 -0.26 2.10

Annual Metrics and Ratios for Akero Therapeutics

This table displays calculated financial ratios and metrics derived from Akero Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -80.37% -26.13% -15.18% -58.32% -63.74%
EBIT Growth		 0.00% -81.02% -27.37% -14.14% -50.12% -65.11%
NOPAT Growth		 0.00% -75.58% -25.87% -14.14% -50.12% -65.11%
Net Income Growth		 0.00% -81.02% -27.23% -11.17% -35.46% -66.09%
EPS Growth		 0.00% 13.10% -14.68% 0.69% -0.70% -29.76%
Operating Cash Flow Growth		 0.00% -98.74% -12.54% -16.11% -57.12% -58.29%
Free Cash Flow Firm Growth		 0.00% 0.00% -13.01% -38.05% -50.85% -54.24%
Invested Capital Growth		 0.00% -26.08% -97.92% 19.86% 41.20% -37.65%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -2.48% 5.40% -28.08% -5.47%
EBIT Q/Q Growth		 0.00% 0.00% -2.70% 5.75% -26.72% -6.00%
NOPAT Q/Q Growth		 0.00% 0.00% -2.70% 5.75% -26.72% -6.00%
Net Income Q/Q Growth		 0.00% 0.00% -2.77% 7.71% -26.85% -6.25%
EPS Q/Q Growth		 0.00% 0.00% -1.05% 14.58% -25.65% 1.06%
Operating Cash Flow Q/Q Growth		 0.00% -19.89% -4.32% 1.27% -18.91% -8.72%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -4.31% -14.18% -9.18%
Invested Capital Q/Q Growth		 0.00% 0.00% -16.39% 27.09% -79.85% 8.83%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 99.89% 97.29% 87.79% 88.31%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -43.00% -40.89% -47.11% -45.20% -35.22% -39.22%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -16.65% -40.89% -47.11% -45.20% -35.22% -39.22%
Return on Equity Simple (ROE_SIMPLE)		 -33.99% -30.62% -59.59% -34.31% -28.35% -33.60%
Net Operating Profit after Tax (NOPAT)		 -32 -56 -71 -81 -121 -200
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.65% -11.41% -13.21% -11.85% -6.94% -8.00%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -23.98% -21.60% -25.44%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -44 -79 -101 -115 -173 -285
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -44 -79 -100 -115 -182 -298
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 4.92 3.46 4.36 7.85 2.43 2.59
Price to Tangible Book Value (P/TBV)		 4.92 3.46 4.36 7.85 2.43 2.59
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.03 0.05 0.05
Long-Term Debt to Equity		 0.00 0.00 0.00 0.03 0.05 0.05
Financial Leverage		 -1.06 -1.04 -1.07 -1.07 -1.03 -1.02
Leverage Ratio		 1.06 1.06 1.10 1.11 1.09 1.09
Compound Leverage Factor		 1.06 1.06 1.09 1.08 0.95 0.97
Debt to Total Capital		 0.00% 0.00% 0.00% 2.84% 4.46% 4.49%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 2.84% 4.46% 4.49%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 97.16% 95.54% 95.51%
Debt to EBITDA		 0.00 0.00 0.00 -0.08 -0.14 -0.12
Net Debt to EBITDA		 0.00 0.00 0.00 2.98 2.99 2.56
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.08 -0.14 -0.12
Debt to NOPAT		 0.00 0.00 0.00 -0.12 -0.21 -0.18
Net Debt to NOPAT		 0.00 0.00 0.00 4.24 4.50 3.82
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.12 -0.21 -0.18
Altman Z-Score		 39.25 35.85 13.86 49.65 16.11 13.90
Noncontrolling Interest Sharing Ratio		 61.28% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 14.73 20.70 7.70 18.61 29.27 19.38
Quick Ratio		 14.56 20.47 7.49 18.42 28.75 18.69
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -54 -61 -84 -127 -196
Operating Cash Flow to CapEx		 0.00% -47,840.54% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -114.22 -41.09 -42.07
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -125.19 -46.91 -49.29
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -125.19 -46.91 -49.29
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -7.67 -9.68 -19 -15 -9.02 -12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -2.00 -9.47 3.80 6.32 -3.40
Enterprise Value (EV)		 497 627 550 2,221 756 1,179
Market Capitalization		 634 896 738 2,563 1,301 1,942
Book Value per Share		 $4.51 $7.45 $4.85 $6.98 $9.61 $10.75
Tangible Book Value per Share		 $4.51 $7.45 $4.85 $6.98 $9.61 $10.75
Total Capital		 129 259 169 336 560 785
Total Debt		 0.00 0.00 0.00 9.54 25 35
Total Long-Term Debt		 0.00 0.00 0.00 9.54 25 35
Net Debt		 -136 -268 -188 -342 -544 -763
Capital Expenditures (CapEx)		 0.00 0.15 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.72 -10 -20 -15 -9.18 -12
Debt-free Net Working Capital (DFNWC)		 129 258 168 336 541 731
Net Working Capital (NWC)		 129 258 168 336 541 731
Net Nonoperating Expense (NNE)		 12 23 30 31 31 52
Net Nonoperating Obligations (NNO)		 -136 -268 -188 -342 -544 -763
Total Depreciation and Amortization (D&A)		 -0.10 0.10 1.11 0.24 -9.08 -12
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.52) ($2.89) ($2.87) ($2.89) ($3.75)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 34.77M 35.01M 38.98M 52.57M 67.14M
Adjusted Diluted Earnings per Share		 $0.00 ($2.52) ($2.89) ($2.87) ($2.89) ($3.75)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 34.77M 34.83M 38.98M 52.57M 67.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.52) ($2.89) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 31.46M 34.83M 46.97M 56.30M 79.62M
Normalized Net Operating Profit after Tax (NOPAT)		 -32 -56 -71 -81 -121 -200
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -155.83 -55.78 -61.14
NOPAT to Interest Expense		 0.00 0.00 0.00 -109.08 -39.05 -42.80
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -155.83 -55.78 -61.14
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -109.08 -39.05 -42.80
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.52% -0.77% -0.51% -0.33%

Quarterly Metrics and Ratios for Akero Therapeutics

This table displays calculated financial ratios and metrics derived from Akero Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -50.30% 20.45% -15.46% -34.00% -38.29% -156.36% -109.84% -87.19% -71.36% -23.63%
EBIT Growth		 -48.20% 21.64% -10.37% -29.12% -29.16% -143.40% -108.51% -84.52% -75.27% -26.11%
NOPAT Growth		 -48.20% 21.64% -10.37% -29.12% -29.16% -143.40% -108.51% -84.52% -75.27% -26.11%
Net Income Growth		 -46.08% 28.88% 0.76% -13.43% -11.58% -139.33% -106.51% -80.12% -83.33% -26.89%
EPS Growth		 -31.43% 52.69% 25.68% 22.08% 22.83% -134.09% -63.64% -35.00% -47.89% 3.88%
Operating Cash Flow Growth		 -68.59% 4.45% -7.68% -14.76% -101.91% -90.63% -42.66% -156.61% -41.64% -37.97%
Free Cash Flow Firm Growth		 -244.13% -63.20% -695.16% -381.36% -135.44% -129.82% -18.39% -60.66% 0.15% -3.20%
Invested Capital Growth		 -27.93% 19.86% 34.92% 22.73% 76.16% 41.20% -84.40% 13.70% -171.54% -37.65%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -30.75% 29.11% -17.25% -23.29% -34.94% -31.42% 4.03% -9.99% -23.53% 5.19%
EBIT Q/Q Growth		 -30.79% 29.57% -13.11% -23.91% -30.83% -32.73% 3.10% -9.65% -24.28% 4.50%
NOPAT Q/Q Growth		 -30.79% 29.57% -13.11% -23.91% -30.83% -32.73% 3.10% -9.65% -24.28% 4.50%
Net Income Q/Q Growth		 -29.70% 35.12% -12.02% -20.33% -27.59% -39.15% 3.34% -4.95% -29.86% 3.69%
EPS Q/Q Growth		 -19.48% 52.17% -25.00% -9.09% -18.33% -45.07% 12.62% 10.00% -29.63% 5.71%
Operating Cash Flow Q/Q Growth		 -26.22% -3.59% 3.43% 9.11% -122.07% 2.20% 27.74% -63.50% -22.58% 4.73%
Free Cash Flow Firm Q/Q Growth		 -229.92% -4.49% -23.66% -12.91% -61.36% -2.00% 36.29% -53.22% -0.29% -5.42%
Invested Capital Q/Q Growth		 8.27% 27.09% 20.10% -44.60% 71.70% -79.85% -150.57% 32.32% 10.97% 8.83%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 97.60% 105.20% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.90% 86.23% 89.84% 87.24% 85.08% 89.19% 88.97% 85.16% 88.99% 89.75%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -44.79% -45.20% -49.39% -30.21% -25.82% -35.22% -31.11% -28.87% -35.90% -39.22%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -44.79% -45.20% -49.39% -30.21% -25.82% -35.22% -31.11% -28.87% -35.90% -39.22%
Return on Equity Simple (ROE_SIMPLE)		 -35.34% 0.00% -36.51% -18.74% -20.52% 0.00% -21.18% -25.58% -32.13% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -18 -20 -25 -33 -43 -42 -46 -57 -55
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.55% -1.99% -2.36% -1.53% -1.48% -2.68% -1.92% -1.38% -2.32% -2.36%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.29% - - - -7.73% - - - -6.95%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -36 -25 -29 -36 -47 -62 -60 -66 -82 -78
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -36 -26 -30 -37 -50 -65 -63 -69 -85 -81
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.72 7.85 5.87 3.79 4.82 2.43 1.68 2.03 2.70 2.59
Price to Tangible Book Value (P/TBV)		 3.72 7.85 5.87 3.79 4.82 2.43 1.68 2.03 2.70 2.59
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.03 0.03 0.08 0.04 0.04 0.05 0.04 0.04 0.05 0.05
Long-Term Debt to Equity		 0.03 0.03 0.08 0.04 0.04 0.05 0.04 0.04 0.05 0.05
Financial Leverage		 -1.07 -1.07 -1.07 -1.05 -1.03 -1.03 -1.03 -1.02 -1.01 -1.02
Leverage Ratio		 1.11 1.11 1.15 1.11 1.10 1.09 1.09 1.08 1.10 1.09
Compound Leverage Factor		 1.12 0.96 1.03 0.97 0.93 0.97 0.97 0.92 0.98 0.98
Debt to Total Capital		 2.68% 2.84% 7.44% 3.86% 4.09% 4.46% 3.95% 4.20% 4.54% 4.49%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.34% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 2.68% 2.84% 7.44% 3.86% 3.74% 4.46% 3.95% 4.20% 4.54% 4.49%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.32% 97.16% 92.56% 96.14% 95.91% 95.54% 96.05% 95.80% 95.46% 95.51%
Debt to EBITDA		 -0.08 -0.08 -0.21 -0.19 -0.17 -0.14 -0.16 -0.14 -0.12 -0.12
Net Debt to EBITDA		 3.00 2.98 2.68 4.94 4.14 2.99 4.05 3.29 2.66 2.56
Long-Term Debt to EBITDA		 -0.08 -0.08 -0.21 -0.19 -0.16 -0.14 -0.16 -0.14 -0.12 -0.12
Debt to NOPAT		 -0.11 -0.12 -0.30 -0.28 -0.26 -0.21 -0.24 -0.21 -0.19 -0.18
Net Debt to NOPAT		 4.26 4.24 3.86 7.20 6.16 4.50 6.08 4.96 3.99 3.82
Long-Term Debt to NOPAT		 -0.11 -0.12 -0.30 -0.28 -0.24 -0.21 -0.24 -0.21 -0.19 -0.18
Altman Z-Score		 20.71 50.48 24.45 29.56 31.98 16.74 12.91 14.21 14.49 14.73
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 14.97 18.61 20.84 29.78 20.25 29.27 30.12 24.89 17.25 19.38
Quick Ratio		 14.82 18.42 20.58 29.60 19.50 28.75 29.86 24.39 16.57 18.69
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -21 -22 -27 -30 -49 -50 -32 -48 -49 -51
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -63.79 -59.66 -58.44 -35.19 -54.80 -55.33 -31.91 -39.36 -38.99 -42.68
Operating Cash Flow to Interest Expense		 -76.00 -70.46 -53.90 -26.12 -55.99 -54.21 -35.46 -46.67 -56.52 -55.91
Operating Cash Flow Less CapEx to Interest Expense		 -76.00 -70.46 -53.90 -26.12 -55.99 -54.21 -35.46 -46.67 -56.52 -55.91
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -21 -15 -12 -18 -5.02 -9.02 -23 -15 -14 -12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -4.60 3.80 6.58 5.22 16 6.32 -10 2.43 -8.61 -3.40
Enterprise Value (EV)		 915 2,221 1,479 1,704 2,224 756 553 809 1,240 1,179
Market Capitalization		 1,279 2,563 1,797 2,339 2,812 1,301 1,422 1,622 1,992 1,942
Book Value per Share		 $9.14 $6.98 $6.52 $12.31 $10.49 $9.61 $15.03 $11.54 $10.63 $10.75
Tangible Book Value per Share		 $9.14 $6.98 $6.52 $12.31 $10.49 $9.61 $15.03 $11.54 $10.63 $10.75
Total Capital		 353 336 331 641 608 560 881 833 773 785
Total Debt		 9.45 9.54 25 25 25 25 35 35 35 35
Total Long-Term Debt		 9.45 9.54 25 25 23 25 35 35 35 35
Net Debt		 -365 -342 -319 -634 -588 -544 -869 -813 -752 -763
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -21 -15 -12 -18 -5.12 -9.18 -23 -15 -14 -12
Debt-free Net Working Capital (DFNWC)		 353 336 331 622 550 541 881 745 704 731
Net Working Capital (NWC)		 353 336 331 622 548 541 881 745 704 731
Net Nonoperating Expense (NNE)		 10 5.27 5.70 6.14 7.03 12 11 9.97 16 15
Net Nonoperating Obligations (NNO)		 -365 -342 -319 -634 -588 -544 -869 -813 -752 -763
Total Depreciation and Amortization (D&A)		 0.11 -0.09 -1.16 -1.25 -3.15 -3.52 -2.81 -3.29 -3.57 -2.82
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.92) ($0.44) ($0.55) ($0.60) ($0.71) ($1.03) ($0.90) ($0.81) ($1.05) ($0.99)
Adjusted Weighted Average Basic Shares Outstanding		 38.66M 38.98M 46.94M 51.87M 55.61M 52.57M 59.31M 69.16M 69.44M 67.14M
Adjusted Diluted Earnings per Share		 ($0.92) ($0.44) ($0.55) ($0.60) ($0.71) ($1.03) ($0.90) ($0.81) ($1.05) ($0.99)
Adjusted Weighted Average Diluted Shares Outstanding		 38.66M 38.98M 46.94M 51.87M 55.61M 52.57M 59.31M 69.16M 69.44M 67.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 46.76M 46.97M 50.09M 55.60M 55.71M 56.30M 69.15M 69.43M 69.80M 79.62M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -18 -20 -25 -33 -43 -42 -46 -57 -55
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -111.39 -70.22 -62.92 -41.57 -52.49 -68.98 -60.50 -53.40 -65.57 -65.02
NOPAT to Interest Expense		 -77.97 -49.15 -44.04 -29.10 -36.75 -48.28 -42.35 -37.38 -45.90 -45.51
EBIT Less CapEx to Interest Expense		 -111.39 -70.22 -62.92 -41.57 -52.49 -68.98 -60.50 -53.40 -65.57 -65.02
NOPAT Less CapEx to Interest Expense		 -77.97 -49.15 -44.04 -29.10 -36.75 -48.28 -42.35 -37.38 -45.90 -45.51
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.60% -0.77% -1.03% -1.12% -0.76% -0.51% -0.42% -0.38% -0.36% -0.33%

Frequently Asked Questions About Akero Therapeutics' Financials

When does Akero Therapeutics's financial year end?

According to the most recent income statement we have on file, Akero Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Akero Therapeutics' net income changed over the last 5 years?

Akero Therapeutics' net income appears to be on an upward trend, with a most recent value of -$252.06 million in 2024, rising from -$43.76 million in 2019. The previous period was -$151.76 million in 2023. Find out what analysts predict for Akero Therapeutics in the coming months.

What is Akero Therapeutics's operating income?
Akero Therapeutics's total operating income in 2024 was -$285.42 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $285.42 million
How has Akero Therapeutics revenue changed over the last 5 years?

Over the last 5 years, Akero Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

How much debt does Akero Therapeutics have?

Akero Therapeutics' total liabilities were at $75.77 million at the end of 2024, a 68.5% increase from 2023, and a 3,135.4% increase since 2017.

How much cash does Akero Therapeutics have?

In the past 7 years, Akero Therapeutics' cash and equivalents has ranged from $64.79 million in 2019 to $340.24 million in 2024, and is currently $340.24 million as of their latest financial filing in 2024.

How has Akero Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Akero Therapeutics' book value per share changed from 4.51 in 2019 to 10.75 in 2024, a change of 138.4%.


Related Companies

This page (NASDAQ:AKRO) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Musk's warning signal: Prepare before the cascade begins
When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...
InvestorPlace | Sponsored
Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...
Priority Gold | Sponsored
Trump to solve American wealth loss?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...
Crypto Swap Profits | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored